Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.

Marta Soares Luís Antunes Patrícia Redondo Marina BorgesRuben HermansDony PatelFiona GrimsonRobin MunroCarlos ChaibLaure LacoinMelinda DaumontJohn R PenrodJohn C O'DonnellMaria José BentoFrancisco Rocha Gonçalves

Published in: BMC pulmonary medicine (2020)

This real-world data analysis from a large Portuguese oncology hospital demonstrates a high disease burden for advanced NSCLC in the pre-immunotherapy era, with nearly one-quarter of patients not receiving SACT. Even in patients receiving SACT, median survival was only about 1 year.

Keyphrases

advanced non small cell lung cancer
data analysis
end stage renal disease
epidermal growth factor receptor
ejection fraction
small cell lung cancer
chronic kidney disease
healthcare
palliative care
prognostic factors
peritoneal dialysis
risk factors
quality improvement
emergency department
free survival